**Original Article**

## Antagonistic Effects of Lactobacilli spp. against Ciprofloxacin-Resistant Uropathogenic Escherichia coli Strains

Mahsa Yeganeh<sup>1</sup>, Hedayat Hosseini<sup>2\*</sup>, Sedigheh Mehrabian<sup>1</sup>, Elham Siasi Torbati<sup>1</sup>, Seyed Morteza Zamir<sup>3</sup>

1-Faculty of Biological Sciences, Tehran-North Branch, Islamic Azad University, Tehran, Iran

2- Department of Food Technology Research, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran

3- Biotechnology Group, Faculty of Chemical Engineering, Tarbiat Modares University, Tehran, Iran

Received: January 2018

Accepted: March 2018

### ABSTRACT

**Background and Objectives:** Recently, the use of probiotics for the treatment of Urinary Tract Infections has become more popular. The use of probiotics in therapy is useful as only a few side effects such as destruction of resistant bacteria or disturbance of the intestinal microbiota have been reported. The aim of this study was to evaluate the probiotic effects of lactic acid bacteria by co-aggregation of ciprofloxacin-resistant uropathogenic *Escherichia coli* strains using microbial techniques.

**Materials and Methods:** Three strains of *Lactobacillus plantarum*, *Lactobacillus casei* and *Lactobacillus acidophilus* were provided. Twenty isolates of uropathogenic *Escherichia coli* were collected from Shahid Labbafinejad hospital, Tehran. Eight samples with resistance to ciprofloxacin were selected using the disk diffusion method for the co-aggregation test. PCR was used to evaluate the presence of *qnrA* and *qnrS* genes in ciprofloxacin-resistant isolates. To evaluate the antimicrobial activity of complete culture and supernatants of lactobacilli, modified double-layer culture method and well diffusion methods were used, respectively. Co-aggregation of lactobacilli was evaluated by the co-aggregation test and microscopy test.

**Results:** Results showed that the eight human isolates were resistant to ciprofloxacin among other samples. Only one strain had both *qnrA* and *qnrS* genes simultaneously. *L. plantarum* with the average growth inhibition zone of 42 mm and with 65% of the co-aggregation had the best probiotic effects among all lactobacilli bacteria.

**Conclusions:** The probiotic lactobacilli had spectacular antimicrobial effects against the ciprofloxacin-resistant uropathogenic *Escherichia coli* strains. Also, lactobacillus spp. were aggregated with uropathogenic *Escherichia coli* strains and preventing from their adhesion to specific receptors on the Urethra, thus, the subsequent invasion to the host was prevented.

**Keywords:** Antimicrobial, Co-aggregation, *Lactobacillus acidophilus*, *Lactobacillus casei*, *Lactobacillus plantarum*

### Introduction

Uropathogenic *E. coli* (UPEC) is one of the major concerns in the food industry. In some cases, the propagation of a single UPEC colony may occur within the population *via* contaminated food (1-3). The emergence of resistance to quinolones, as a type of antibiotics, among gram negative bacteria, limits the benefit of use of these antibiotics (4, 5). Among the quinolones, ciprofloxacin has the most effect against both gram-negative and gram-positive bacteria (6). Ciprofloxacin prevents from rebuilding,

translating, and regeneration of bacterial DNA through the inhibition of the DNA gyrase in gram negative bacteria and topoisomerase IV in gram-positive bacteria (7,8). Resistance to ciprofloxacin is due to the mutation in the chromosome-dependent subunit A of DNA gyrase (9). Besides, the *qnr* genes are responsible for the plasmid resistance to quinolones by preventing the inhibition effect of ciprofloxacin on DNA gyrase and topoisomerase enzymes (10-12).

On the other hand, lactic acid bacteria (LAB), capable of producing lactic acid, are gram positive and non-spore forming (13,14). LAB are widely used as the starters in the fermentation to produce dairy products. *Lactobacillus* spp. are considered as the most important genus of LAB (15,16), producing different compounds such as bacteriocin, lactic acid, and hydrogen peroxide, which prevent the growth of some pathogenic bacteria in food (17,18). Various diarrheal illnesses have been successfully treated by LAB as probiotic bacteria (19, 20). One of the characteristics of LAB is their co-aggregation with some pathogenic bacteria. Co-aggregation is the result of cell-to-cell recognition between two different bacterial strains. The co-aggregation properties of probiotic strains with pathogens prevent the adhesion of pathogenic bacteria through competing for binding sites in the urinary tract. Consequently, the use of LAB as the probiotics with the co-aggregation properties can be very useful and practical for the prevention of colonization of pathogens in body tissues (21). Therefore, the ability to co-aggregate is a desirable feature for probiotics in food safety (22).

Therefore, the aim of the present study was to investigate the antagonistic effects of *Lactobacillus* spp. against ciprofloxacin-resistant UPEC strains.

## Materials and Methods

**Bacterial strains:** To confirm genus and species of *E. coli* strains, after cultivation in eosin methylene blue medium and observing the colonies with metallic luster, some conventional biochemical tests (indol, MR-VP, urea, simon citrate, motility and TSI) were carried out. Also, gram staining and microscopic observation confirmed the presence of *E. coli* strains in medium culture. *E. coli* ATCC 25922 was used as a control in this study and was purchased from the Persian Type Culture Collection. *Lactobacillus plantarum* (ATCC 136H3), *L. acidophilus* (ATCC 314), and *L. casei* (ATCC 25598) strains were provided by Pasteur Institute of Iran. To activate the bacterial cultures, lactobacilli strains were cultured in MRS broth and MRS agar medium under anaerobic conditions and were incubated at 37 °C for 72 h and UPEC strains were cultured under aerobic conditions and incubated at 37 °C for 24 h.

**Antimicrobial drug susceptibility testing:** The antimicrobial drug susceptibility profiles were performed by Kirby-Bauer method. A volume of 100 µl of an overnight culture of each UPEC isolate was plated and streaked on Mueller-Hinton agar medium. The routinely used 15 antibiogram discs, including Nalidixic acid, Amikacin, Ampicillin, Sulfamethoxazole / Trimethoprim, Ofloxacin, Cefoxitin, Norfloxacin, amoxicillin/clavulanate, Tobromycin, Gentamicin, Piperacillin/ tazobactam, Imipenem, Ciprofloxacin, Ceftizoxime, Nitrofurantoin (Padtan Teb, Iran) were placed on the surface of the inoculated plates. Then, the plates were incubated at 37°C for 24 h. The samples were evaluated by the presence or absence of the growth inhibition zone. The strains without any inhibition zone were considered as resistant to antibiotics (23, 24).

**DNA extraction and polymerase chain reaction:** To identify the resistance to ciprofloxacin in eight UPEC strains, *qnrA* and *qnrS* genes were analyzed by the PCR method. First, an optimized boiling method was used for DNA extraction (Table 1). UPEC strains were grown in Luria-Bertani Broth (Merck, Germany) at 37 °C overnight. Then, the bacteria were pelleted from 1.5 ml Luria-Bertani broth and suspended in sterile distilled water (200 µl) and incubated at 37 °C for 10 min and centrifuged. To amplify sequences of the *qnrA*, *qnrS* genes, specific primers were used. Detection of adhesion-encoding genes (*qnrA*, *qnrS*) was done by multiplex PCR (Bio-Rad, America). The reactions (25 µl) consisted of 2 µl templates DNA, 10 pmol l<sup>-1</sup> of each primer, and 12.5 µl of a ready-to-use 2X PCR Master Mix Red by IBRC Taq DNA polymerase, with the amplification conditions of; initial denaturation at 94 °C for 10 min, followed by 35 DNA cycles of denaturation at 94°C for 2 min, annealing at a specific temperature and extension at 72°C for 1 min. The PCR product (5 µl) underwent gel electrophoresis (Syngene G:BOX, America) on agarose (1% w. w-1) (Merck, Germany), followed by staining with ethidium bromide solution (Cinna colon, Iran). Amplified DNA elements of specific sizes were indicated by UV-induced fluorescence and the size of the amplicons was estimated by comparing with the 1 kb DNA ladder (Thermo Scientific, America) included on the same gel (25-27).

**Table 1.** Acquired primer for PCR of qnr gene and Annealing temperature

Annealing temperature	Identified gen	Primer sequencing	Company	Size
56° for 30 sec	qnrA	5-AGA GGA TTT CTC ACG CCA GG-3	Cinna Gen	562 bp
		5-TGC CAG GCA CAG ATC TTG AC-3		
55° for 30 sec	qnrS	5-ACG ACA TTC GTC AAC TGC AA -3	Cinna Gen	417 bp
		5- TAA ATT GGC ACC CTG TAG GC - 3		

### Antimicrobial effect of lactobacillus spp. complete cultures by modified double-layer method:

To examine the antimicrobial effect of lactobacillus spp., first, 50 µl of the newly cultured probiotic lactobacilli in pasteurized milk were spotted in the center of MRS agar (Merck, Germany) plate. After 24 h of incubation and growth of lactobacilli, the melted Mueller-Hinton agar (Merck, Germany) was poured on palte, then it was cooled down to room temperature to get solid. Then, suspensions of UPEC strains with turbidity of 0.5 McFarland were cultured on the Mueller-Hinton agar and incubated at 37 °C for 24 h. This test was carried out separately for each UPEC strain and control sample. Then, the growth-inhibited zones of the samples were evaluated and reported as mm of the observed diameter (28).

### Antimicrobial activity of cell free supernatants (CFS) against UPEC strains using agar well diffusion assay:

Targeted colony of eight strains of UPEC were diluted using 0.1% w w-1 peptone water (Merck, Germany) to reach 0.5 McFarland Turbidity Standard. All targeted UPEC strains being used were freshly spread onto Muller Hilton Agar using Kirby Bauer technique. Then, 5 mm diameter size of wells were immediately made up in each plate. Overnight suspensions of inoculated lactobacilli in milk were centrifuged at 12000×g for 30 min. The isolated supernatants were filtered by sterile filter 0.25 µ. Then, 80 µl of obtained supernatants were transferred to each well separately. Each plate was controlled by adding sterilized peptone water. All plates were incubated aerobically at 37°C for 24 h. The inhibition zones were measured in all of the plates. *E. coli* ATCC 25922 was used as controls in the experiments. The experiments were carried out and repeated three times (29).

**Co-aggregation of lactobacillus spp. with UPEC strains:** *Lactobacillus* spp. strains were grown

anaerobically. The culture were then harvested by using centrifugation at 10000× g for 10 min, and were washed twice with sterile PBS consisting of (g/L): KH<sub>2</sub>PO<sub>4</sub>, 0.34; K<sub>2</sub>HPO<sub>4</sub>, 1.21; NaCl, 8.0; pH 7.0 and re-suspended in PBS. Two mL of each *Lactobacillus* spp. suspensions was mixed with 2 mL of the UPEC strains suspensions for 10 s at least by a vortex mixer. Then, they were incubated (both aerobically and anaerobically) for 4 h at 37°C, the suspensions were measured using a Bioscreen C (DNV, Finland) at OD<sub>600nm</sub> (T1800; Hitachi, Tokyo, Japan) with co-aggregation expressed as follows according to Handley *et al* (30):

$$Co - aggregation = \frac{[(A_x + A_y) / 2] - A_{(x+y)}}{(A_x + A_y) / 2} \times 100$$

Equation1: where A represents absorbance, x and y represent each of the two strains in the control tubes, and (x + y) represents their mixture (32, 33).

**Statistical analysis:** All experiments were carried out in triplicates. Statistical analysis was performed through analysis of variance (ANOVA) using IBM SPSS & Duncan Statistics Software version 19. A *p*-value ≤ 0.05 was considered to be statistically significant.

## Results and Discussion

### Identification of *E. coli* strains by biochemical analysis:

*E. coli* strains were identified by biochemical analysis. The results indicated that all isolates were positive indole, positive MR-VP, negative urea, and negative simon citrate, Except for one strain, other strains were able to move, and in terms of TSI were acid / acid. Table 2 shows the results of performed biochemical tests on UPEC isolates producing urinary tract infections. Table 2 shows all of the biochemical tests for UPEC strains.

**Table 2.** Identification of *E. coli* strains by biochemical analysis

Number of strain	Simon Sitrat	Urea	MR-VP	Indol	Motility	TSI
UPEC 1	-	-	+	+	+	A/A
UPEC 2	-	-	+	+	+	A/A
UPEC 3	-	-	+	+	+	A/A
UPEC4	-	-	+	+	+	A/A
UPEC5	-	-	+	+	-	A/A
UPEC6	-	-	+	+	+	A/A
UPEC7	-	-	+	+	+	A/A
UPEC8	-	-	+	+	+	A/A


TSI, Triple Sugar Iron Agar

**Antimicrobial drug susceptibility testing:** The effects of fifteen different antibiotics were tested on all twenty strains of UPEC. The results indicated that eight strains were resistant to ciprofloxacin antibiotic. In the present study, the resistance to ciprofloxacin was 40%, much greater than for other fourteen antibiotics. Therefore, the isolates showed high resistance to ciprofloxacin antibiotic. Since the large amount prescription of ciprofloxacin initially to treat urinary tract infections from 1962, resistance to this antibiotic is expected to be higher than other quinolone antibiotics. In a study by Nakhjavani *et al*, in 2007, on isolated *E. coli* strains from patients with urinary tract infections, resistance to ciprofloxacin was 40.2% (34). By comparing the results of this study with the research carried out by Nakhjavani *et al*, it was observed that the level of resistance to ciprofloxacin in UPEC strains has been almost stable in the recent years. In a study in Pakistan in 2011, resistance of *E. coli* isolates to ciprofloxacin was 36.45% (35). The high prevalence to ciprofloxacin resistance in this study may be due to excess

consumption of ciprofloxacin without any official supervision in developing countries.

In United States in 2006, resistance of *E. coli* strains was reported 21% to quinolones and 12% to fluoroquinolones (36). The difference between the results of the study in the US and the present study in terms of the level of resistance may be due to more detailed health-monitoring programs and lack of availability of these types of antibiotics for all people in the US.


**Identification of *qnr* genes in UPEC isolates:** Electrophoresis of PCR product has been shown in Figure 1 to identify *qnrA* and *qnrS* genes, on the 1% agarose gel with a 1000 bp marker. These genes are responsible for resistance to ciprofloxacin (37). By using PCR method for isolates with phenotypic resistance to ciprofloxacin, it was determined that among thirteen isolates resistant to ciprofloxacin, only one isolate had both *qnrA* and *qnrS* genes and two isolates had only *qnrS* gene. In the present study, the prevalences of *qnrA* and *qnrS* genes in ciprofloxacin-resistant isolates were 7.7% and 23.1%, respectively.



**Figure 1.** Electrophoresis of PCR product for *qnrA* and *qnrS* genes on 1% agarose gel in UPEC strain  
 s1,s2 ,s3 = *qnrS*  
 a1,a2,a3= *qnrA*

In China, resistance to ciprofloxacin was about 60% of the clinical isolates of *E.coli* during the period of 1997-1999 (38). Increasing the resistance to ciprofloxacin in Enterobacteriaceae is associated with an increase in the prevalence of PMQR genes, diversity of PMQR genes and the prevalence of mutations in *gyrA* and *parC* genes or both in positive PMQR strains (39). Corkille *et al.*, in 2005, investigated the resistant of enterobacteria to ciprofloxacin and cefotaxime, related to bacteremia disease in the UK, found that prevalence of *qnrA* gene in the studied isolates was 32% (40). High prevalence of *qnrA* gene in the UK study compared to this study (7.7%) can be due to the fact that the UK study was carried out on isolates obtained from patients in ICU with high consumption of antibiotic. The findings of the present study also showed that some isolates without *qnrA* gene still have a phenotypic resistance to ciprofloxacin probably due to other *qnr* genes or other mechanisms of resistance to this antibiotic, such as mutation in ciprofloxacin targeted enzymes.

**Antimicrobial effect of lactobacillus spp. complete culture by modified double-layer method:** The antimicrobial effect of lactobacilli complete culture showed that *L. plantarum*, *L. casei*, and *L. acidiphylus* had maximum antimicrobial effect against UPEC strains with the growth-inhibited zone of 42 mm, 32 mm, and 28mm, respectively. The antimicrobial effect of complete culture of lactobacilli against UPEC strains and *E.coli* ATCC 25922 (control strain) has been shown in Figure 2.




**Figure 2.** Antimicrobial effect of lactobacilli complete culture by modified double layer method (mm)

There are several methods for the evaluation of the antimicrobial properties of the complete culture of probiotics against pathogens. The best method is the one proposed by Mc given and Tagg in 1971, entitled as "Spot on-lawn method". In 2001, Maia changed its name to double-layer culture method (41). Then, this method was modified by Arbab Soleimani *et al.*, in 2010 (modified double layer method). In this method, the antimicrobial effect of probiotic complete cultures is well visible in the second layer of culture medium despite the inhibition zone of UPEC strains (42). The results showed that antimicrobial effects of *L. plantarum* and *L. caesi* complete cultures against UPEC strains were more than *L. acidophilus*. It should be noted that the antimicrobial effects of complete culture of *L. plantarum* and *L. casei* were not significantly different.

Anas *et al.*, announced that complete culture of *L. plantarum* had antimicrobial effect against *E. coli* and *Staphylococcus aureus*. This finding is in accordance with the findings of this study (43).

**Antimicrobial activity of lactobacillus spp. supernatants against UPEC strains using agar well diffusion assay:** The antimicrobial effect of lactobacilli supernatant against UPEC showed that *L. plantarum*, *L. casei*, and *L. acidiphylus* had maximum antimicrobial effect against UPEC strains with the growth-inhibited zone of 32 mm, 29 mm, and 20 mm, respectively. The antimicrobial effects of lactobacilli supernatant against UPEC strains and *E.coli* ATCC 25922 (control strain) are shown in Figure 3.



**Figure 3.** Antimicrobial effect of lactobacilli supernatants against UPEC strains by well diffusion method (mm)

The antimicrobial effect of cells-free supernatants (CFSs) derived from probiotic bacteria can be due to two reasons: The first reason is the production of lactic acid or acetic acid by probiotics resulting the decrease of pH of the culture. Pathogenic bacteria are naturally sensitive to acidic conditions and are destroyed in acidic conditions. The second reason is the production of bacteriocin as an antimicrobial compound by probiotics (13).

Ogunbanwo *et al.* showed that supernatants resulted from the two probiotics of *L. plantarum* and *L. brevis* can inhibit the growth of *E. coli*, *Bacillus cereus* and *Yersinia enterocolitica* (44). The results of that study are similar to this research regarding the antimicrobial effect of *L. plantarum* against *E. coli*.


Several recent reports have documented the various antibacterial activities of CFSs of lactobacilli strains. In contrast, Hawaz observed that, filtered supernatants from some of the lactobacilli strains did not exhibit any inhibition against *Staphylococcus*, *E. coli*, and *Klebsiella* sp. (45). Recently, Jose *et al.* reported that the lactobacilli supernatant could inhibit the growth of *E. coli* (46). Additionally, few lactobacilli isolates from dairy products had antagonistic activity against *Listeria* sp. Also, other researchers reported high antagonistic activity against *B.cereus* as well. Furthermore, Rao *et al.*, showed that different strains of *L. plantarum* and *L. pentosus* have significant antimicrobial activities against *B. subtilis*, *Pseudomonas aeruginosa*, and *S. aureus* and other pathogenic bacteria (47).

#### Co-aggregation of lactobacillus spp. with UPEC:

The results showed that the co-aggregation of *L. plantarum* with UPEC strains was higher than other present lactobacilli and the average co-aggregation was 41.5%. While, the average co-aggregations of *L. casei* and *L. acidophilus* with UPEC strains were 30.2 % and 34.2 %, respectively. Co-aggregation percent of lactobacilli strains and UPEC strains are shown in Figure 4.

One of the capabilities of the probiotic lactobacilli is that they can trap and accumulate with pathogenic bacteria, thus, the activity of pathogenic bacteria is stopped and inhibited. Cell aggregation between the microorganisms of the same strain (auto-aggregation), or between genetically different strains (co-aggregation) have significant importance in several ecological niches (48). There are several reports stating that probiotic lactobacilli can create a

significant defense mechanism for the host against the pathogenic strains through cellular accumulation mechanism with pathogens. In additions, lactobacilli may act against pathogens by the production of antimicrobial agents such as organic acids, hydrogen peroxide, and bacteriocin (49). But, the mechanisms of cellular accumulation with pathogens have not been recognized yet. Cesena *et al.*, (50), Jankovic *et al.*, (48), and Collado *et al.*, (51), described several methods for measuring the cellular accumulation of probiotics. The results confirmed that lactobacilli could accumulate with tested UPEC strains with high percentages and thus, inhibited the growth of UPEC strains.



**Figure 4.** Co-aggregation percentage of lactobacilli with UPEC strains

Arbab Soleimani *et al.*, found that co-aggregation effect of *L. casei* with UPEC strains was higher than *L. acidophilus* (52). This finding was similar to the findings from this study. This study has found 61% co-aggregation for *L. casei* and 46% co-aggregation for *L. acidophilus*, indicating more co-aggregation effects than the present research.

The relationship between the lactobacilli co-aggregation and their antimicrobial power has been proposed in recent years (52). According to the present study, as the co-aggregation of probiotic Lactobacilli increased, their antimicrobial power of complete culture increased.

Furthermore, the cell surface characteristics of bacteria probably plays an important role in the co-aggregation. It was suggested that lactobacilli

adherence is related to surface hydrophobicity, proteins or some other compounds such as carbohydrate and lipoteichoic acid (53). In a study, heat and pepsin had significant effects on the co-aggregation of *L. acidophilus* S1 with *E. coli* ATCC 11229, indicating that a proteinaceous surface component mediates the co-aggregation. However, sodium periodate did not have any effect on the co-aggregation, showing that carbohydrates are not involved in the co-aggregation process (54).

Moreover, it has been proved that the presence of *fim* gene expression, attributing to the presence of fimbriae in *E. coli* strains is important for the generation of co-aggregation with probiotic *L. casei* (55). It should be pointed out that *fim* gene was also identified in UPEC strains capable of co-aggregating with lactobacilli in this research.

### Conclusions

It can be concluded that the complete cultures and supernatants resulted from *L. plantarum* ATCC 136H3, *L. casei* ATCC 25598, and *L. acidophilus* ATCC 314 had inhibitory effects against UPEC strains. However, *L. plantarum* ATCC 136H3 showed higher co-aggregation (41.5%) with UPEC strains among all lactobacilli. In general, the antimicrobial effect of complete culture of lactobacilli against UPEC strains was more than their supernatants, probably due to production of antimicrobial metabolites and acidic conditions or direct competition with pathogens for binding to the present receptors on the surface of the cells.

It can be also stated that co-aggregation can be associated with the antimicrobial agents of complete culture. Further research is required to better understand the antimicrobial mechanism of lactobacilli complete culture to treat the urinary tract infection (UTI) and prevent from the formation of a strain resistant to antibiotics. Therefore, application of probiotics in food stuff inhibits the growth of pathogens and prevents from food spoilage. Therefore, the application of probiotics as food preservatives is recommended.

### Acknowledgement

This article is the result of a research project in National Nutrition and Food Technology Research Institute. We would like to thank the National Nutrition and Food Technology Research Institute (NNFTRI) affiliated with Shahid Beheshti University

of Medical Sciences, and Faculty of Biological Science, Islamic Azad University, North-Tehran Branch, Tehran, Iran.

### Financial disclosure

The authors declared no financial interest.

### Funding/Support

This work was supported by National Nutrition and Food Technology Research Institute (NNFTRI) of Shahid Beheshti University of Medical Sciences, Tehran, Iran.

### References

1. Price SB, Wright JC, DeGraves FJ, Castanie-Cornet MP, Foster JW. Acid resistance systems required for survival of *Escherichia coli* H7:O157 in the bovine gastrointestinal tract and in apple cider are different. *Appl Environ Microbiol.* 2004; 70: 4792–4799. DOI: 10.1128/AEM.70.8.4792-4799.2004
2. Wiles TJ, Kulesus RR, Mulvey MA. Origins and Virulence Mechanisms of Uropathogenic *Escherichia coli*. *Exp Mol Pathol.* 2008; 85(1): 11–19. DOI: 10.1016/j.yexmp.2008.03.007
3. Kanjee U, Houry WA. Mechanisms of acid resistance in *Escherichia coli*. *Annu Rev Microbiol.* 2013; 67: 65–81. DOI: 10.1146/annurev-micro-092412-155708.
4. Azap Ö, Togan T, Yesilkaya A, Arslan H, Haberal M. Antimicrobial susceptibilities of uropathogen *Escherichia coli* in renal transplant recipients: dramatic increase in ciprofloxacin resistance. *Transplant Proc.* 2013; 45: 956-7. DOI: 10.1016/j.transproceed.2013.03.006
5. Pakzad I, Ghafourian S, Taherikalani M, sadeghifard N, Abtahi H, Rahbar M, Mansory Jamshidi N. Qnr prevalence in extended spectrum beta-lactamases (ESBLs) and none-ESBLs producing *Escherichia coli* isolated from urinary tract infections in central of Iran. *Iran J Basic Med Sci.* 2011; 14:458-64.
6. Bonkat G, Muller G, Braissant O, Frei R, Tschudin-Suter S, Rieken M, Wyler S, Gasser TC, Bachmann A, Widmer AF. Increasing prevalence of ciprofloxacin resistance in extended-spectrum-beta-lactamase-producing *Escherichia coli* urinary isolates. *World J Urol.* 2013; 31:1427-32. DOI: 10.1007/s00345-013-1031-5.
7. Bansal S, Tandon V. Contribution of mutations in DNA gyrase and topoisomerase IV genes to ciprofloxacin resistance in *Escherichia coli* clinical isolates. *Int J Antimicrob Agent.* 2011; 37:253-5. DOI: 10.1016/j.ijantimicag.2010.11.022.

8. Shin JH, Jung HJ, Lee JY, Kim HR, Lee JN, Chang CL. High rates of plasmid-mediated quinolone resistance QnrB variants among ciprofloxacin-resistant *Escherichia coli* and *Klebsiella pneumoniae* from urinary tract infections in Korea. *Microb Drug Resist*. 2008; 14:221-6. DOI: 10.1089/mdr.2008.0834.
9. Montasir M, Jayedul H, Nazmul Hussain N, Alimul I, Khalada Z, Bahanur R, Tanvir R. Prevalence and Molecular Detection of Quinolone-Resistant *E.coli* in Rectal Swab of Apparently Healthy Cattle in Bangladesh. *Int J Trop Dis Health*. 2017; 24(2): 1-7. DOI: 10.9734/IJTDH/2017/34404
10. Yoon Sung H, Sook S, Yong Ho P, Kun Taek P. Prevalence and Mechanism of Fluoroquinolone Resistance in *Escherichia coli* isolated from swine Feces in Korea. *Int J Food Prot*. 2017; 7: 1145–1151. DOI:10.4315/0362-028X.JFP-16-502
11. Cremet L, Caroff N, Dauvergne S, Reynaud A, Lepelletier D, Corvec S. Prevalence of plasmid-mediated quinolone resistance determinants in ESBL Enterobacteriaceae clinical isolates over a 1-year period in a French hospital. *Pathologie Biologie*. 2011; 59:151-6. DOI: 10.1016/j.patbio.2009.04.003
12. Corkill JE, Anson JJ, Hart CA. High prevalence of the plasmid-mediated quinolone resistance determinant qnrA in multidrug-resistant Enterobacteriaceae from blood cultures in Liverpool, UK. *J Antimicrob Chemother*. 2005; 56:1115-7.
13. Aasen IM, Mørretrø T, Katla T, Axelsson L, Storrø I. Influence of complex nutrients, temperature and pH on bacteriocin production by *Lactobacillus sakei* CCUG 42687. *Appl Microbiol Biotechnol*. 2000; 53: 159-166.
14. Suskovic J, Kos B, Goreta J, Matošić S. Role of Lactic Acid Bacteria and bifidobacteria in synbiotic effect. *Food Technol Biotechnol*. 2001; 39: 227-235
15. Djomne VS, Ngoufack FZ, Pierre MK, Alberto C, Florence F. Probiotic properties of lactobacilli strains isolated from raw cow milk in the western highlands of Cameroon. *Innovative Rom Food Biotechnol*. 2011; 9: 12-28.
16. Coeuret V, Dubernet S, Bernardeau M, Gueguen M, Vernoux J. Isolation, characterisation and identification of lactobacilli focusing mainly on cheeses and other dairy products. *Lait*. 2003; 83: 269–306. DOI: 10.1051/lait:2003019
17. Oyetayo VO, Adetuyi FC, Akinyosoye FA. Safety and protective effect of *Lactobacillus acidophilus* and *Lactobacillus casei* used as probiotic agent in vivo. *Afr J Biotech*. 2003; 2: 448-452.
18. Abdelbasset M, Djamila K. Antimicrobial activity of autochthonous lactic acid bacteria isolated from Algerian traditional fermented milk Raïb. *Afr J Biotechnol*. 2003; 7: 2908-2914.
19. O'Horo JC, Jindai K, Kunzer B, Safdar N. Treatment of recurrent *Clostridium difficile* infection: a systematic review. *Infect*. 2014; 42(1): 43-59.
20. Maragkoudakis PA, Zoumpopoulou G, Miaris C, Kalantzopoulos G, Pot B, Tsakalidou E. Probiotic potential of Lactobacillus strains isolated from dairy products. *Int Dairy J*. 2006; 16: 189-199.
21. Kos B, Susković J, Vuković S, Simpraga M, Frece J, Matosić S. Adhesion and aggregation ability of probiotic strain *Lactobacillus acidophilus* M92. *J Appl Microbiol*. 2003; 94: 981-987. DOI: 10.1046/j.1365-2672.2003.01915.x
22. Garcia-Cayuela T, Korany AM, Bustos I, Gomez de Cadinanos LP, Requena T, Pelaez C, Carmen Martinez-Cuesta M. Adhesion abilities of dairy Lactobacillus plantarum strains showing an aggregation phenotype. *Food Res Int*. 2014; 57: 44-50.
23. Saira B, Yasra S, Aamir A, Mashkoo M, Muhammad Azeem S, Ayesha T, and Abdul H. multiple drug resistance patterns in various phylogenetic groups of Uropathogenic *E. coli* isolated from faisalabad region of Pakistan. *Braz J Microbiol*. 2011 Oct; 42(4):1278-83.
24. Bukh AS, Schonheyder HC, Emmersen JM, Sogaard M, Bastholm S, Roslev P. *Escherichia coli* phylogenetic groups are associated with site of infection and level of antibiotic resistance in community-acquired bacteraemia: a 10 year population-based study in Denmark. *J Antimicrob Chemother*. 2009 Jul;64(1):163-8.
25. Bonkat G, Müller G, Braissant O, Frei R, Tschudin-Suter S, Rieken M, Wyler S, Gasser TC, Bachmann A, Widmer AF. Increasing prevalence of ciprofloxacin resistance in extended-spectrum-beta-lactamase-producing *Escherichia coli* urinary isolates. *World J Urol*. 2013;31:1427-32. DOI: 10.1007/s00345-013-1031-5.
26. Corkill JE, Anson JJ, Hart CA. High prevalence of the plasmid-mediated quinolone resistance determinant qnrA in multidrug-resistant Enterobacteriaceae from blood cultures in Liverpool, UK. *J Antimicrob Chemother*. 2005;56:1115-7.
27. Putnam SD, Sanders JW, Tribble DR, Rockabrand DR, Riddle MS, Rozmajzl PJ, Frenck RW. Posttreatment changes in *Escherichia coli* antimicrobial susceptibility rates among diarrheic patients treated with ciprofloxacin. *Antimicrob Agent Chemother*. 2005; 49:2571-2.
28. Soleimani NA, Kermanshahi RK, Yakhchali B, Sattari TN. Antagonistic activity of probiotic lactobacilli



- against *Staphylococcus aureus* isolated from bovine mastitis. *Afr J Microbiol Res.* 2010; 4 (20): 2169-2173.
29. Asahara T, Nomoto K, Watanuki M, Yokokura T. Antimicrobial activity of intraurethrally administered probiotic *Lactobacillus casei* in a murine model of *Escherichia coli* urinary tract infection. *Antimicrob. Agents Chemother.* 2001; 45 (6):1751- 60.
  30. Handley SP *et al.* A comparison of the adhesion, coaggregation and cell surface hydrophobicity properties of fibrillar and fimbriate strains of *Streptococcus salivarius*. *J Gen Microbiol.* 1987; 133: 3207-3217.
  31. Collado M C, Meriluoto J, and Salminen S. Adhesion and aggregation properties of probiotic and pathogen strains. *Eur Food Res Technol.* 2008; 22(6):1065-73. Doi:10.1007/s00217-007-0632-x
  32. Vlkova E, Rada V, Šmehilova M, Killer J. Auto-Aggregation and Co-Aggregation Ability in Bifidobacteria and Clostridia. *Folia Microbiol.* 2008; 53(3): 263–269 .
  33. Kolenbrander PE. Co-aggregation of human oral bacteria: potential role in the accretion of dental plaque. *J. Appl. Bacteriol.* 1993;74:79S–86S.
  34. Akbari-Nakhjavani F, Mirsalehi A, Hamidian M, Kazemi B, Mirafshar M, Jabal Ameli F, et al. Antimicrobial susceptibility testing of *Escherichia coli* strains isolated from urinary tract infections to fluoroquinolones and detection of *gyrA* mutations in resistant strains. *Daru.* 2007; 15(2): 94-9.
  35. Muhammad I, Uzma M, Yasmin B, Mehmood Q, Habib B. Prevalence of antimicrobial resistance and integrons in *Escherichia coli* from Punjab, Pakistan. *Braz J Microbiol.* 2011; 42(3): 462-6.
  36. Moreno E, Prats G, Sabate M, Perez T, Johnson JR, Andreu A. Quinolone, fluoroquinolone and trimethoprim/sulfamethoxazole resistance in relation to virulence determinants and phylogenetic background among uropathogenic *Escherichia coli*. *Antimicrob Agents Chemother.* 2006; 57(2): 204-11.
  37. Robicsek A, Jacoby GA, Hooper DC. The worldwide, emergence of plasmid mediated quinolone resistance. *Lancet Infect Dis.* 2006; 6(1):629-40.
  38. Wang H, Dzink-Fox JL, Chen M, Levy SB. Genetic characterization of highly fluoroquinolone resistant clinical *Escherichia coli* strains from china: rule of *acrR* mutations. *Antimicrob Agents Chemother.* 2001; 45(5):1515-21.
  39. Bouchakour M, Zerouali KH, Claude JD, Amarouch H, Mdaghri NE, Courvalian P, et al. Plasmid-mediated quinolone resistance in expanded spectrum beta-lactamase producing *enterobacteriaceae* in Morocco. *J Infect Dev Contr.* 2010; 12(4): 799-803.
  40. Corkill JE, Anson JJ, Hart CA. High prevalence of the plasmid-mediated quinolone resistance determinant *qnrA* in multidrug-resistant *Enterobacteriaceae* from blood cultures in Liverpool, UK. *J Antimicrob Chemother.* 2005;56(3): 1115–17.
  41. Maia OB, Duarte R, Silva AM, Cara DC, Nicoli JR. Evaluation of the components of a commercial probiotic in gnotobiotic mice experimentally challenged with *Salmonella enterica* subsp. *enterica* ser. Typhimurium. *Vet microb.* 2001; 20;79(2):183-9.
  42. Soleimani NA, Kermanshahi RK, Yakhchali B, Sattari TN. Antagonistic activity of probiotic *lactobacilli* against *Staphylococcus aureus* isolated from bovine mastitis. *Afr J Microbiol Res.* 2010; 4 (20): 2169- 73.
  43. Anas M, Eddine HJ, Mebrouk K. Antimicrobial activity of *Lactobacillus* species isolated from Algerian raw goat's milk against *Staphylococcus aureus*. *World J Dairy Food Sci.* 2008;3(2):39-49.
  44. Ogunbanwo ST, Sanni AL, Onilude AA. Characterization of bacteriocin produced by *Lactobacillus plantarum* F1 and *Lactobacillus brevis* OG1. *Afr J Biotechnol.* 2003; 2(8): 219-27
  45. Hawaz E. Isolation and identification of lactic acid bacteria from curd and in vitro evaluation of its growth inhibition activities against pathogenic bacteria. *Afr J Microbiol Res.* 2014; 8:1419–1425.
  46. Jose NM, Bunt CR, Hussain MA. Comparison of microbiological and probiotic characteristics of lactobacilli isolates from dairy food products and animal rumen contents. *Microorganisms.* 2015; 3:198–212.
  47. Rao KP, Chennappa G, Suraj U, Nagaraja H, Raj CAP, Sreenivasa MY. Probiotic potential of *Lactobacillus* strains isolated from sorghum-based traditional fermented food. *Probiotics Antimicrob Proteins.* 2015; 7(2):146–156.
  48. Jankovic I, Ventura M, Meylan V, Rouvet M, Elli M, Zink R. Contribution of aggregation-promoting factor to maintenance of cell shape in *Lactobacillus gasseri* 4B2. *J Bacteriol.* 2003; 185:3288–96.
  49. Schachtsiek M, Hammes WP., Hertel C. Characterization of *Lactobacillus coryniformis* DSM 20001T surface protein Cpf mediating coaggregation with and aggregation among pathogens. *Appl. Environ. Microbiol.* 2004; 70 (12): 7078–7085.
  50. Cesena C, Morelli L, Alander M, Siljander T, Tuomola E, Salminen S, Mattila-Sandholm T, Vilpponen-Salmela T, Von Wright A. *Lactobacillus*

- crispatus and its nonaggregating mutant in human colonization trials. *J dairy sci.* 2001; 84(5):1001-10.
51. Collado MC, Meriluoto J, Salminen S. Interactions between pathogens and lactic acid bacteria: aggregation and coaggregation abilities. *Eur.J.Food Res.Technol.* 2007; 10 (7):0632.
52. Ershadian M, Arbab Soleimani N, Ajoudanifar H, Vaezi Khakhki MR. The Antimicrobial and Co-aggregation effects of probiotic *lactobacilli* against some pathogenic bacteria. *Iran J Med Microbiol.*2015; 9(3): 14-22.
53. Vandevoorde L, Christiaens H, Verstraete W. Prevalence of co-aggregation reactions among chicken lactobacilli. *J Appl Microbiol.* 1992; 72: 214–9.
54. Ekmekci H, Aslim B, Ozturk S. Characterization of vaginal lactobacilli co-aggregation ability with *Escherichia coli*. *Microbiol Immunol.* 2009; 53:59–65
55. Pilipcineca E, Huismanb TT, Willemsenb PTJ, Appelmelkc BJ, Graaf FK, Oudega B. Identification by Tn10 transposon mutagenesis of host factors involved in the biosynthesis of K99 fimbriae of *Escherichia coli*: Effect of LPS core mutations. *FEMS Microbiol. Lett.* 1994;123:201–206.